MedPath

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Phase 1
Completed
Conditions
Melanoma (Skin)
Metastatic Cancer
Interventions
Biological: sargramostim
Registration Number
NCT00017121
Lead Sponsor
Alliance for Clinical Trials in Oncology
Brief Summary

RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung.

PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metastatic to the lung.

Detailed Description

OBJECTIVES:

* Determine immunomodulatory effects of aerosolized sargramostim (GM-CSF) in patients with metastatic melanoma to the lung (part A).

* Determine toxicity profile of this therapy, in terms of pulmonary and hematologic toxicity, in these patients.

* Determine, preliminarily, the therapeutic effects of this therapy, in terms of progression-free survival, overall survival, and objective response rate, in these patients.

* Determine the maximum tolerated dose of GM-CSF in these patients (part B).

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).

* Part A: Cohorts of 5-10 patients receive escalating doses of GM-CSF until the optimal immunostimulatory dose (ISD) is determined. The optimal ISD is defined as the dose at which at least 7 of 10 patients experience immunostimulation. Once the optimal ISD is determined, 10 patients receive aerosolized GM-CSF at a dose halfway between the optimal ISD and the preceding dose. Dose escalation is discontinued if at least 2 of 5 or at least 4 of 10 patients on a particular dose level experience dose-limiting toxicity.

* Part B: Cohorts of 3-6 patients receive escalating doses of GM-CSF until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.

After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years.

PROJECTED ACCRUAL: A total of 85 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
sargramostimsargramostimPatients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B). After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years.
Primary Outcome Measures
NameTimeMethod
Progression-free survivalUp to 6 years
Secondary Outcome Measures
NameTimeMethod
Progression-free survivalUp to 6 years
Overall survivalUp to 6 years
Objective response rateUp to 6 years

Trial Locations

Locations (87)

Rush-Copley Cancer Care Center

🇺🇸

Aurora, Illinois, United States

McDonough District Hospital

🇺🇸

Macomb, Illinois, United States

Graham Hospital

🇺🇸

Canton, Illinois, United States

Memorial Hospital

🇺🇸

Carthage, Illinois, United States

Galesburg Clinic

🇺🇸

Galesburg, Illinois, United States

CCOP - Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

Haematology-Oncology Associates of Ohio and Michigan, PC

🇺🇸

Lambertville, Michigan, United States

Medcenter One Hospital Cancer Care Center

🇺🇸

Bismarck, North Dakota, United States

St. Alexius Medical Center Cancer Center

🇺🇸

Bismarck, North Dakota, United States

Northwest Ohio Oncology Center

🇺🇸

Maumee, Ohio, United States

St. Luke's Hospital

🇺🇸

Maumee, Ohio, United States

Geisinger Medical Center

🇺🇸

Danville, Pennsylvania, United States

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

🇺🇸

Wilkes-Barre, Pennsylvania, United States

Mayo Clinic Scottsdale

🇺🇸

Scottsdale, Arizona, United States

Mayo Clinic - Jacksonville

🇺🇸

Jacksonville, Florida, United States

St. Joseph Medical Center

🇺🇸

Bloomington, Illinois, United States

Eureka Community Hospital

🇺🇸

Eureka, Illinois, United States

Galesburg Cottage Hospital

🇺🇸

Galesburg, Illinois, United States

Mason District Hospital

🇺🇸

Havana, Illinois, United States

Hopedale Medical Complex

🇺🇸

Hopedale, Illinois, United States

Joliet Oncology-Hematology Associates, Limited - West

🇺🇸

Joliet, Illinois, United States

Kewanee Hospital

🇺🇸

Kewanee, Illinois, United States

BroMenn Regional Medical Center

🇺🇸

Normal, Illinois, United States

Community Hospital of Ottawa

🇺🇸

Ottawa, Illinois, United States

Community Cancer Center

🇺🇸

Normal, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Ottawa

🇺🇸

Ottawa, Illinois, United States

Cancer Treatment Center at Pekin Hospital

🇺🇸

Pekin, Illinois, United States

CCOP - Illinois Oncology Research Association

🇺🇸

Peoria, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Peoria

🇺🇸

Peoria, Illinois, United States

Methodist Medical Center of Illinois

🇺🇸

Peoria, Illinois, United States

Illinois Valley Community Hospital

🇺🇸

Peru, Illinois, United States

Perry Memorial Hospital

🇺🇸

Princeton, Illinois, United States

OSF St. Francis Medical Center

🇺🇸

Peoria, Illinois, United States

St. Margaret's Hospital

🇺🇸

Spring Valley, Illinois, United States

Carle Cancer Center at Carle Foundation Hospital

🇺🇸

Urbana, Illinois, United States

Cedar Rapids Oncology Associates

🇺🇸

Cedar Rapids, Iowa, United States

Saint Anthony Memorial Health Centers

🇺🇸

Michigan City, Indiana, United States

CCOP - Iowa Oncology Research Association

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates at John Stoddard Cancer Center

🇺🇸

Des Moines, Iowa, United States

John Stoddard Cancer Center at Iowa Methodist Medical Center

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates at Mercy Cancer Center

🇺🇸

Des Moines, Iowa, United States

Mercy Cancer Center at Mercy Medical Center - Des Moines

🇺🇸

Des Moines, Iowa, United States

John Stoddard Cancer Center

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates - West Des Moines

🇺🇸

West Des Moines, Iowa, United States

Mercy Memorial Hospital System

🇺🇸

Monroe, Michigan, United States

Hickman Cancer Center at Bixby Medical Center

🇺🇸

Adrian, Michigan, United States

Community Cancer Center of Monroe

🇺🇸

Monroe, Michigan, United States

Fairview Southdale Hospital

🇺🇸

Edina, Minnesota, United States

Fairview Ridges Hospital

🇺🇸

Burnsville, Minnesota, United States

Mercy and Unity Cancer Center at Mercy Hospital

🇺🇸

Coon Rapids, Minnesota, United States

Mercy and Unity Cancer Center at Unity Hospital

🇺🇸

Fridley, Minnesota, United States

Minnesota Oncology Hematology, PA at Maplewood Cancer Center

🇺🇸

Maplewood, Minnesota, United States

CCOP - Metro-Minnesota

🇺🇸

Saint Louis Park, Minnesota, United States

Park Nicollet Health Services

🇺🇸

St. Louis Park, Minnesota, United States

United Hospital

🇺🇸

St. Paul, Minnesota, United States

Hubert H. Humphrey Cancer Center at North Memorial Medical Center

🇺🇸

Robbinsdale, Minnesota, United States

Ridgeview Medical Center

🇺🇸

Waconia, Minnesota, United States

Minnesota Oncology Hematology, PA - Woodbury

🇺🇸

Woodbury, Minnesota, United States

Mid Dakota Clinic, PC

🇺🇸

Bismarck, North Dakota, United States

Bismarck Cancer Center

🇺🇸

Bismarck, North Dakota, United States

Wood County Oncology Center

🇺🇸

Bowling Green, Ohio, United States

Lima Memorial Hospital

🇺🇸

Lima, Ohio, United States

Fremont Memorial Hospital

🇺🇸

Fremont, Ohio, United States

St. Charles Mercy Hospital

🇺🇸

Oregon, Ohio, United States

Toledo Clinic - Oregon

🇺🇸

Oregon, Ohio, United States

North Coast Cancer Care, Incorporated

🇺🇸

Sandusky, Ohio, United States

Firelands Regional Medical Center

🇺🇸

Sandusky, Ohio, United States

Flower Hospital Cancer Center

🇺🇸

Sylvania, Ohio, United States

Toledo Hospital

🇺🇸

Toledo, Ohio, United States

St. Vincent Mercy Medical Center

🇺🇸

Toledo, Ohio, United States

Medical University of Ohio Cancer Center

🇺🇸

Toledo, Ohio, United States

Mercy Hospital of Tiffin

🇺🇸

Tiffin, Ohio, United States

CCOP - Toledo Community Hospital

🇺🇸

Toledo, Ohio, United States

Toledo Clinic, Incorporated - Main Clinic

🇺🇸

Toledo, Ohio, United States

Fulton County Health Center

🇺🇸

Wauseon, Ohio, United States

Geisinger Medical Group - Scenery Park

🇺🇸

State College, Pennsylvania, United States

Avera Cancer Institute

🇺🇸

Sioux Falls, South Dakota, United States

Sioux Valley Hospital and University of South Dakota Medical Center

🇺🇸

Sioux Falls, South Dakota, United States

Medical X-Ray Center, PC

🇺🇸

Sioux Falls, South Dakota, United States

Hematology-Oncology Associates of Fredericksburg, Incorporated

🇺🇸

Fredericksburg, Virginia, United States

Virginia Piper Cancer Institute at Abbott-Northwestern Hospital

🇺🇸

Minneapolis, Minnesota, United States

Proctor Hospital

🇺🇸

Peoria, Illinois, United States

Mercy Capitol Hospital

🇺🇸

Des Moines, Iowa, United States

Mayo Clinic Cancer Center

🇺🇸

Rochester, Minnesota, United States

Immanuel Medical Center

🇺🇸

Omaha, Nebraska, United States

Alegant Health Cancer Center at Bergan Mercy Medical Center

🇺🇸

Omaha, Nebraska, United States

Creighton University Medical Center

🇺🇸

Omaha, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath